Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma

Abstract Although next-generation sequencing (NGS) data on lymphomas require further validation before being implemented in daily practice, the clinical application of NGS can be considered right around the corner. The aim of our study was to validate an NGS lymphoid panel for tissue and liquid biop...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mariana Bastos-Oreiro, Julia Suárez-González, Cristina Andrés-Zayas, Natalia Carolina Carrión, Solsiré Moreno, Diego Carbonell, María Chicano, Paula Muñiz, Laura Sanz, Francisco Javier Diaz-Crespo, Javier Menarguez, José Luis Diez-Martín, Ismael Buño, Carolina Martínez-Laperche
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a75623e012414b5894cf984d944e1284
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a75623e012414b5894cf984d944e1284
record_format	dspace
spelling	oai:doaj.org-article:a75623e012414b5894cf984d944e12842021-11-28T12:15:55ZIncorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma10.1038/s41598-021-02362-42045-2322https://doaj.org/article/a75623e012414b5894cf984d944e12842021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02362-4https://doaj.org/toc/2045-2322Abstract Although next-generation sequencing (NGS) data on lymphomas require further validation before being implemented in daily practice, the clinical application of NGS can be considered right around the corner. The aim of our study was to validate an NGS lymphoid panel for tissue and liquid biopsy with the most common types of non-Hodgkin’s lymphoma [follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)]. In this series, 372 somatic alterations were detected in 93.6% (44/47) of the patients through tissue biopsy. In FL, we identified 93 somatic alterations, with a median of 7.4 mutations per sample. In DLBCL, we detected 279 somatic variants with a median of 8.6 mutations (range 0–35). In 92% (24/26) of the cases, we were able to detect some variant in the circulating tumor DNA. We detected a total of 386 variants; 63.7% were detected in both types of samples, 13.2% were detected only in the circulating tumor DNA, and 23% were detected only in the tissue biopsy. We found a correlation between the number of circulating tumor DNA mutations, advanced stage, and bulky disease. The genetic alterations detected in this panel were consistent with those previously described at diagnosis. The liquid biopsy sample is therefore a complementary tool that can provide new genetic information, even in cases where a solid biopsy cannot be performed or an insufficient sample was obtained. In summary, we describe and analyze in this study the findings and difficulties encountered when incorporating liquid biopsy into clinical practice in non-Hodgkin’s lymphoma at diagnosis.Mariana Bastos-OreiroJulia Suárez-GonzálezCristina Andrés-ZayasNatalia Carolina CarriónSolsiré MorenoDiego CarbonellMaría ChicanoPaula MuñizLaura SanzFrancisco Javier Diaz-CrespoJavier MenarguezJosé Luis Diez-MartínIsmael BuñoCarolina Martínez-LapercheNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mariana Bastos-Oreiro Julia Suárez-González Cristina Andrés-Zayas Natalia Carolina Carrión Solsiré Moreno Diego Carbonell María Chicano Paula Muñiz Laura Sanz Francisco Javier Diaz-Crespo Javier Menarguez José Luis Diez-Martín Ismael Buño Carolina Martínez-Laperche Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma
description	Abstract Although next-generation sequencing (NGS) data on lymphomas require further validation before being implemented in daily practice, the clinical application of NGS can be considered right around the corner. The aim of our study was to validate an NGS lymphoid panel for tissue and liquid biopsy with the most common types of non-Hodgkin’s lymphoma [follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)]. In this series, 372 somatic alterations were detected in 93.6% (44/47) of the patients through tissue biopsy. In FL, we identified 93 somatic alterations, with a median of 7.4 mutations per sample. In DLBCL, we detected 279 somatic variants with a median of 8.6 mutations (range 0–35). In 92% (24/26) of the cases, we were able to detect some variant in the circulating tumor DNA. We detected a total of 386 variants; 63.7% were detected in both types of samples, 13.2% were detected only in the circulating tumor DNA, and 23% were detected only in the tissue biopsy. We found a correlation between the number of circulating tumor DNA mutations, advanced stage, and bulky disease. The genetic alterations detected in this panel were consistent with those previously described at diagnosis. The liquid biopsy sample is therefore a complementary tool that can provide new genetic information, even in cases where a solid biopsy cannot be performed or an insufficient sample was obtained. In summary, we describe and analyze in this study the findings and difficulties encountered when incorporating liquid biopsy into clinical practice in non-Hodgkin’s lymphoma at diagnosis.
format	article
author	Mariana Bastos-Oreiro Julia Suárez-González Cristina Andrés-Zayas Natalia Carolina Carrión Solsiré Moreno Diego Carbonell María Chicano Paula Muñiz Laura Sanz Francisco Javier Diaz-Crespo Javier Menarguez José Luis Diez-Martín Ismael Buño Carolina Martínez-Laperche
author_facet	Mariana Bastos-Oreiro Julia Suárez-González Cristina Andrés-Zayas Natalia Carolina Carrión Solsiré Moreno Diego Carbonell María Chicano Paula Muñiz Laura Sanz Francisco Javier Diaz-Crespo Javier Menarguez José Luis Diez-Martín Ismael Buño Carolina Martínez-Laperche
author_sort	Mariana Bastos-Oreiro
title	Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma
title_short	Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma
title_full	Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma
title_fullStr	Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma
title_full_unstemmed	Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma
title_sort	incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-hodgkin’s lymphoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a75623e012414b5894cf984d944e1284
work_keys_str_mv	AT marianabastosoreiro incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT juliasuarezgonzalez incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT cristinaandreszayas incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT nataliacarolinacarrion incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT solsiremoreno incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT diegocarbonell incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT mariachicano incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT paulamuniz incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT laurasanz incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT franciscojavierdiazcrespo incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT javiermenarguez incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT joseluisdiezmartin incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT ismaelbuno incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma AT carolinamartinezlaperche incorporationofnextgenerationsequencinginclinicalpracticeusingsolidandliquidbiopsyforpatientswithnonhodgkinslymphoma
_version_	1718408094157897728

Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma

Ejemplares similares